What are the considerations for using eculizumab in pediatric patients?

See full prescribing information for Soliris. Soliris™ (eculizumab),. Concentrated solution for intravenous infusion. Initial U.S. Approval: 2007. WARNING: ... Aug 15, 2018 ... Reported relapse rates in aHUS after stopping eculizumab are as high as 30%, suggesting indefinite therapy is reasonable and that patients who choose to stop ... Jun 21, 2024 ... Soliris (eculizumab) is a monoclonal antibody that's approved for patients with atypical hemolytic uremic syndrome (aHUS). It specifically works ... Soliris 300 mg concentrate for solution for infusion. Active Ingredient: eculizumab. Company: Alexion Pharma UK Ltd. See contact details. Eculizumab injection is used to treat a type of blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Nov 24, 2020 ... Soliris is not intended for acute treatment of a NMOSD relapse. Route of administration: Intravenous (IV) infusion. Dosage: Patients must be ... Indicated for paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Doses 1-4: 600 mg IV qWeek for first 4 weeks, followed by Dose 5: 900 mg IV 1 week ... Jul 27, 2023 ... Soliris (eculizumab) has been approved in the European Union (EU) for expanded use to include the treatment of refractory generalised myasthenia ... MEDICATION GUIDE. SOLIRIS® (so-leer-is). (eculizumab) injection, for intravenous use. What is the most important information I should know about SOLIRIS? Eculizumab is a monoclonal antibody that prevents the activation of terminal complement in some autoimmune conditions. ... Eculizumab has a long duration of ...